2 completed, 1 withdrawn. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
Follow Cadent Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of CAD-1883 for Spinocerebellar Ataxia CAD-1883, Placebos - Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1 | Phase 2 | Withdrawn | Cadent Therapeutics | 2021-06-01 | 2021-04-08 | |
| Study of CAD-9303 in Subjects With Schizophrenia CAD-9303, Placebos - Schizophrenia | Phase 1 | Completed | Cadent Therapeutics | 103 | 2020-02-28 | 2021-12-15 |
| A Clinical Study to Evaluate CAD-1883 in Essential Tremor CAD-1883 - Essential Tremor | Phase 2 | Completed | Cadent Therapeutics | 25 | 2019-01-23 | 2021-08-05 |
Ataxia (1) · Essential Tremor (1) · Machado-Joseph Disease (1) · Olivopontocerebellar Atrophy V (1) · Schizophrenia (1) · Spinocerebellar Ataxia 10 (1) · Spinocerebellar Ataxias (1) · Spinocerebellar ataxia 8 (1)
United States (3)